Similar articles

• Recent advances in the renin-angiotensin system: angiotensin-converting enzyme 2 and (pro)renin receptor.

  Raizada MK, Paton JF. Raizada MK, et al. Exp Physiol. 2008 May;93(5):517-8. doi: 10.1113/expphysiol.2008.042861. Exp Physiol. 2008. PMID: 18448661 No abstract available.
• [Renin, prorenin, and the direct renin inhibitor aliskiren].

  Slabý A, Zák A. Slabý A, et al. Cas Lek Cesk. 2010;149(2):55-60. Cas Lek Cesk. 2010. PMID: 20662466 Review. Czech.
• [Development of hypertension and RAAS].

  Ichihara A. Ichihara A. Nihon Jinzo Gakkai Shi. 2009;51(4):433-7. Nihon Jinzo Gakkai Shi. 2009. PMID: 19601548 Review. Japanese. No abstract available.
• The Bothrops legacy: vasoactive peptides from Brazil.

  Luft FC. Luft FC. J Renin Angiotensin Aldosterone Syst. 2008 Mar;9(1):57-64. doi: 10.3317/jraas.2008.009. J Renin Angiotensin Aldosterone Syst. 2008. PMID: 18404610 No abstract available.
• Rational of the use of aliskiren in hypertension and beyond.

  Westermann D, Savvatis K, Schultheiss HP, Tschöpe C. Westermann D, et al. Minerva Cardioangiol. 2009 Dec;57(6):761-72. Minerva Cardioangiol. 2009. PMID: 20019651 Review.